A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Epistemonikos ID: 17a17d5c69b940f9d1c0c11285cf3e6fbd9c72ca
First added on: May 09, 2024